For many years, treatment of severe hypoglycemia has remained relatively stagnant requiring use of a multistep, injection kit in order to administer glucagon. This complex task to be orchestrated during a stressful time was prone to error, or even the decision to forgo treatment. Thus, alternate glucagon formulations have been explored, with nasal glucagon administration first being assessed in the 1980s. Over the past decade, studies of nasal glucagon have gone from rigorous inpatient trials to outpatient assessments with real-world application of the product. This presentation will review these trials, as well as simulation studies and provide updates regarding use of nasal glucagon as it has become commercially available.